Loading clinical trials...
Loading clinical trials...
Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim
Conditions
Interventions
Avatrombopag Oral Tablet
Locations
20
United States
Sobi Site 110
Tucson, Arizona, United States
Sobi Site 119
Whittier, California, United States
Sobi Site 123
Washington D.C., District of Columbia, United States
Sobi Site 129
Miami, Florida, United States
Sobi Site 120
Ocala, Florida, United States
Sobi Site 125
St. Petersburg, Florida, United States
Start Date
March 15, 2021
Primary Completion Date
January 3, 2024
Completion Date
January 3, 2024
Last Updated
January 16, 2025
NCT05070845
NCT07039422
NCT07007962
NCT07104565
NCT07362238
NCT07362199
Lead Sponsor
Sobi, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions